Disease
Multiple Myeloma
A plasma-cell hematologic malignancy, treated with induction, autologous transplant where eligible, and continuous/maintenance therapy across proteasome inhibitor, IMiD, anti-CD38, and (increasingly) bispecific/CAR-T drug classes.
Total attributable cost
$13.7B
$67,608/patient
Drug spend
$6.7B
$33,012/patient
49% of total cost is drugs
All stages, prevalent population (2023 SEER estimate) · US